ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00861627
Recruitment Status : Completed
First Posted : March 13, 2009
Last Update Posted : December 2, 2015
Sponsor:
Information provided by (Responsible Party):
Oncolytics Biotech

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 2015
  Actual Study Completion Date : November 2015